摘要 |
The present invention relates in general to prevention, reduction or treatment of rejection in transplant patients. In particular the invention relates to the use of SSRIs (selective serotonin reuptake inhibitors) for the prevention, reduction or treatment of rejection in transplant patients, such as blood cell, stem cell, bone marrow, tissue or organ rejection. |